Investigating how renal nerves affect heart failure treatment with SGLT2 inhibitors
Novel target mechanism (renal nerves) for the beneficial actions of SGLT2 inhibition in congestive heart failure
['FUNDING_R01'] · UNIVERSITY OF NEBRASKA MEDICAL CENTER · NIH-10881799
This study is looking at how a type of diabetes medication called SGLT2 inhibitors can help people with congestive heart failure by reducing fluid buildup in the body, and it aims to find out how the nerves in the kidneys play a role in this process.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF NEBRASKA MEDICAL CENTER (nih funded) |
| Locations | 1 site (OMAHA, UNITED STATES) |
| Trial ID | NIH-10881799 on ClinicalTrials.gov |
What this research studies
This research explores the role of renal nerves in the treatment of congestive heart failure (CHF) using SGLT2 inhibitors, which are commonly prescribed for type 2 diabetes. The study aims to understand how these inhibitors can help reduce sodium and fluid retention, a major issue in CHF, by examining their effects on renal sympathetic nerve activity. By analyzing changes in SGLT2 expression and activity in the kidneys, the research seeks to uncover new mechanisms that could enhance treatment outcomes for patients with heart failure. The findings may lead to improved therapeutic strategies for managing CHF.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with congestive heart failure, particularly those who may also have type 2 diabetes.
Not a fit: Patients with heart failure who do not have any renal involvement or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with congestive heart failure, potentially reducing hospitalizations and improving survival rates.
How similar studies have performed: Previous studies have shown promising results with SGLT2 inhibitors in heart failure management, indicating that this approach has potential based on existing evidence.
Where this research is happening
OMAHA, UNITED STATES
- UNIVERSITY OF NEBRASKA MEDICAL CENTER — OMAHA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PATEL, KAUSHIK P — UNIVERSITY OF NEBRASKA MEDICAL CENTER
- Study coordinator: PATEL, KAUSHIK P
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cardiorenal disease, Cardiorenal syndrome